Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,789 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05241093 | A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 18 | Tarapeutics Science Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05272293 | Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 |
| clinicaltrials |
| NCT05334693 | Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05605379 | CML Pediatric ITK Response According to Molecular Identification at Diagnosis(CML Piramid) | unknown | — | 88 | University Hospital, BordeauxOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06553638 | Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)(PRODIGE) | unknown | — | 50 | University Hospital, BrestOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT02897297 | Myeloproliferative Neoplastic Diseases Observatory From Brest(OBENE) | unknown | — | 1,000 | University Hospital, BrestOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT00899223 | Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes | unknown | — | 1,500 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06263387 | Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine(VENAZA) | unknown | — | 230 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06512610 | ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML | unknown | — | 100 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT03450512 | Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy(DECLAM) | unknown | — | 170 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04365179 | Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML | unknown | Phase 1 | 18 | Immune System Key LtdINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06486350 | IL-6: A Marker for AML Chemo Sensitivity | unknown | — | 72 | Fujian Medical University Union HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06481332 | Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis (CASTETTE)(CASTETTE) | unknown | — | 300 | University Hospital, BrestOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06481345 | Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)(CARPEDIEM) | unknown | — | 300 | University Hospital, BrestOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06476535 | Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy(OPIUM) | unknown | — | 100 | University Hospital, BrestOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06469047 | Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia(RBSNAAMCL) | unknown | — | 80 | Second Hospital of Shanxi Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05304156 | Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"(DYNHAEMICS) | unknown | — | 200 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06432556 | Study of Cellular Heterogeneity in Patients With Mastocytosis(MastCellHet) | unknown | N/A | 26 | University Hospital, ToulouseOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT01305499 | A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 52 | Hetty CarrawayOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT05241106 | A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 15 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT04655118 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | unknown | Phase 2 | 121 | Telios Pharma, Inc.INDUSTRY | 13 | May 10, 2024 | clinicaltrials |
| NCT05832320 | Optimum Induction Therapy of Low-risk APL | unknown | N/A | 74 | Peking University People's HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06251102 | Real-world Ruxolitinib Experience in PV(REVIEW) | unknown | — | 153 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT05758610 | A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients | unknown | Phase 1 | 60 | Shengke Pharmaceuticals (Jiangsu) Limited, ChinaINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT06367673 | Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03682029 | Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies(EVITA) | unknown | N/A | 109 | Rigshospitalet, DenmarkOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT04460950 | Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms | unknown | — | 237 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03481868 | EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors(EPIK) | unknown | N/A | 160 | University Hospital, Clermont-FerrandOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03412409 | RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT | unknown | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT04470947 | Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies(EXALT-2) | unknown | — | 150 | Medical University of ViennaOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06279494 | Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors | unknown | Phase 1 / Phase 2 | 6 | Peking University People's HospitalOTHER | 0 | Mar 21, 2024 | clinicaltrials |
| NCT03291444 | CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | unknown | Phase 1 | 30 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06285136 | Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult | unknown | Phase 2 / Phase 3 | 40 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT02192619 | National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup | unknown | — | 500 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03599960 | Combination Chemotherapy in Patients With Newly Diagnosed BPDCN(LpDessai) | unknown | Phase 2 | 26 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06246006 | Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia(MPL - NPM) | unknown | — | 30 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06233890 | The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia(TIRE) | unknown | — | 50 | Imperial College Healthcare NHS TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06218771 | A Study of TQB3454 Tablets in Patients With Blood Tumors | unknown | Phase 1 / Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | unknown | Phase 1 / Phase 2 | 22 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06188182 | D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia | unknown | — | 60 | Assiut UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT06177366 | A New Blood Score for Myelofibrosis Staging(FIBROMOELLE) | unknown | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Dec 20, 2023 | clinicaltrials |
| NCT06162325 | Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients | unknown | — | 45 | Peking Union Medical College HospitalOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03193281 | KISS Study: Kinase Inhibition With Sprycel Start up(KISS) | unknown | Phase 2 | 91 | University of Auckland, New ZealandOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 15 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04989335 | Bisantrene Combination for Resistant AML | unknown | Phase 2 | 29 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Apr 10, 2025source: clinicaltrials